Antonio Lopez-Beltran

Summary

Country: Spain

Publications

  1. Lopez Beltran A, Montironi R, Raspollini M, Cheng L, Netto G. Iatrogenic pathology of the urinary bladder. Semin Diagn Pathol. 2018;35:218-227 pubmed publisher
    ..Immunohistochemical approach to reactive urothelium from CIS using CK20, p53, and CD44 may also be of utility in the pos-therapy scenario. ..
  2. Lopez Beltran A, Bassi P, Pavone Macaluso M, Montironi R. Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis. Eur Urol. 2004;45:257-66 pubmed
    ..The urologists have a great role in assisting pathologists in the proper examination by providing them with clinical information. ..
  3. Lopez Beltran A, Bassi P, Pavone Macaluso M, Montironi R. Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis. A joint proposal of the European Society of Uropathology and the Uropathology Working Group. Virchows Arch. 2004;445:103-10 pubmed
    ..The urologists have a great role in assisting pathologists in the proper examination by providing them with clinical information. ..
  4. Lopez Beltran A, Kirkali Z, Cheng L, Egevad L, Regueiro J, Blanca A, et al. Targeted therapies and biological modifiers in urologic tumors: pathobiology and clinical implications. Semin Diagn Pathol. 2008;25:232-44 pubmed
    ..The current status of biological and clinicopathological aspects of targeted therapy in prevalent urologic tumors is reviewed. ..
  5. Lopez Beltran A, Requena M, Montironi R, Blanca A, Cheng L. Plasmacytoid urothelial carcinoma of the bladder. Hum Pathol. 2009;40:1023-8 pubmed publisher
    ..Morphological distinction from other malignant neoplasms with plasmacytoid phenotype is critical for its clinical management. ..
  6. Lopez Beltran A, Montironi R, Egevad L, Caballero Vargas M, Scarpelli M, Kirkali Z, et al. Genetic profiles in renal tumors. Int J Urol. 2010;17:6-19 pubmed publisher
    ..Understanding of the molecular genetics of renal tumors is beneficial in making accurate diagnoses, assessing prognoses, and selecting appropriate and targeted therapeutic options. ..
  7. Lopez Beltran A, Carrasco J, Cheng L, Scarpelli M, Kirkali Z, Montironi R. 2009 update on the classification of renal epithelial tumors in adults. Int J Urol. 2009;16:432-43 pubmed publisher
    ..This review emphasizes clinical, pathological and genetic features defining renal epithelial tumors in adults. ..
  8. Lopez Beltran A, Paner G, Blanca A, Montironi R, Tsuzuki T, Nagashima Y, et al. Lymphoepithelioma-like carcinoma of the upper urinary tract. Virchows Arch. 2017;470:703-709 pubmed publisher
    ..Morphologic recognition and distinction from other (non-)neoplastic lesions with prominent lymphoid stroma are critical for its clinical management. ..
  9. Volavšek M, Blanca A, Montironi R, Cheng L, Raspollini M, Vau N, et al. Digital versus light microscopy assessment of surgical margin status after radical prostatectomy. Virchows Arch. 2018;472:451-460 pubmed publisher
    ..Alternatively, reporting the number of blocks with PSM 1 vs. 2 or more might also provide important prognostic data in practice. ..

More Information

Publications16

  1. Lopez Beltran A, Eble J, Bostwick D. Pleomorphic giant cell carcinoma of the prostate. Arch Pathol Lab Med. 2005;129:683-5 pubmed
    ..Pleomorphic giant cell carcinoma is a rare variant of prostatic adenocarcinoma with a poor prognosis that should be considered in the differential diagnosis of prostatic pleomorphic tumors...
  2. Lopez Beltran A, MacLennan G, Montironi R. Cyclin E as molecular marker in the management of breast cancer: a review. Anal Quant Cytol Histol. 2006;28:111-4 pubmed
    ..The role of cyclin E in the prognosis and therapy of breast cancer is reviewed according to recent publications. ..
  3. Lopez Beltran A, Montironi R, Blanca A, Cheng L. Invasive micropapillary urothelial carcinoma of the bladder. Hum Pathol. 2010;41:1159-64 pubmed publisher
    ..The morphologic diversity of micropapillary carcinoma may represent a diagnostic pitfall in limited samples, where its distinction from conventional urothelial carcinoma is critical for its clinical management...
  4. Lopez Beltran A. Rare lesions and tumors of the urinary bladder. Selected issues. Tumori. 2012;98:274-7 pubmed publisher
    ..We emphasize the peculiar features of these variants because some may require different/specific therapeutic approaches...
  5. Lopez Beltran A, Requena M, Alvarez Kindelan J, Quintero A, Blanca A, Montironi R. Squamous differentiation in primary urothelial carcinoma of the urinary tract as seen by MAC387 immunohistochemistry. J Clin Pathol. 2007;60:332-5 pubmed
    ..027) and increases with grade/stage mainly in bladder carcinoma (grade, p = 0.05; stage, p = 0.005). Stage Ta/T1 bladder carcinomas with SqD recurred more (p = 0.021). In conclusion, Mac387 efficiently shows SqD in urothelial tumours...
  6. Lopez Beltran A, Blanca A, Montironi R, Cheng L, Regueiro J. Pleomorphic giant cell carcinoma of the urinary bladder. Hum Pathol. 2009;40:1461-6 pubmed publisher
    ..In limited samples, it may be misdiagnosed as secondary carcinoma or sarcoma, a pitfall of paramount importance for its clinical management...
  7. Lopez Beltran A, Ordonez J, Otero A, Blanca A, Sevillano V, Sanchez Carbayo M, et al. Cyclin D3 gene amplification in bladder carcinoma in situ. Virchows Arch. 2010;457:555-61 pubmed publisher
    ..06 (95% (confidence interval (CI)), 15.5-23.6); mean progression (months) occurred at 23.8?±?1.46 (95% (CI), 20.9-26.7). Our study suggests that Cyclin D3 gene amplification might be a predictor of aggressiveness in BCG-treated CIS. ..